Telehealth Drug Oversight: Gaps Watchdogs See

Key Takeaways

State-level variation in peptide and controlled-substance prescribing rules creates regulatory arbitrage that allows telehealth platforms to sidestep stricter jurisdictions, according to research published in Sexual Medicine.
Off-label ketamine prescribing via direct-to-consumer telehealth carries significant liability and ethical risks that current federal and state frameworks have not adequately addressed, per a Psychiatric Services analysis.
A global scoping review in Neurological Sciences found that telemedicine documentation standards remain inconsistent, undermining the clinical accountability needed for safe remote prescribing.
Research in the Journal of Telemedicine and Telecare identified stigma, regulatory barriers, and inconsistent prescribing rules as major obstacles to equitable telemedicine-enabled opioid use disorder treatment worldwide.
A study from Indonesia published in the Journal of Epidemiology and Global Health found community pharmacists operating telepharmacy services with virtually no regulatory support, a pattern that mirrors early-stage gaps seen in U.S. telehealth markets.

The Regulatory Patchwork: How State-by-State Rules Create Prescribing Loopholes

No single federal rule governs what a telehealth provider can prescribe across state lines — and that gap lets some platforms exploit inconsistent state laws to offer medications in permissive states that stricter states would block.

The United States has never built a unified telehealth prescribing framework. Licensing, prescribing authority, and controlled-substance rules all vary by state, which means a platform incorporated in one state can route prescriptions through a provider licensed in a more permissive jurisdiction, effectively sidestepping the patient’s home-state protections. The American College of Physicians has formally identified this fragmentation as a structural problem, calling for consistent national standards precisely because the current patchwork creates uneven patient protections depending on where someone happens to live.

The consequences are concrete and measurable:

Ketamine prescribing. Direct-to-consumer telehealth platforms have used state-level variation to prescribe off-label ketamine with minimal in-person evaluation requirements. A peer-reviewed analysis of liability and ethics in this space found that some platforms operate in regulatory gray zones where no state authority has clearly claimed oversight — leaving patients without a reliable safety net if something goes wrong.
Peptide therapies. Researchers studying sexual medicine found that state-level rules directly determine whether peptides are available to patients at all, with availability shifting dramatically based on compounding pharmacy regulations and prescriber rules that differ across jurisdictions. A patient in one state may receive a peptide prescription through a telehealth visit; a patient two states over cannot — not because the science changed, but because the rules did.
Opioid use disorder medications. Buprenorphine prescribing via telehealth expanded under federal COVID-era waivers, but global research on telemedicine-enabled MOUD shows that inconsistent regulatory environments remain a primary barrier to equitable access — and a source of confusion about what platforms can legally offer.

Patients rarely know which state’s rules actually govern their prescription. A platform’s website may list a headquarters address, but the prescribing provider may be licensed in a different state entirely, and the compounding pharmacy filling the order may operate under a third state’s rules. Three jurisdictions. Zero transparency.

The ACP’s position paper argues that telehealth policy must prioritize patient safety over market convenience — a standard the current state-by-state system structurally fails to meet.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any medical decisions.

Off-Label and Unguarded: Ketamine, Peptides, and DTC Liability Risks

Disclaimer: This section contains general informational content only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any decisions about your care.

Direct-to-consumer telehealth platforms selling off-label ketamine and compounded peptides carry measurable liability risks for both providers and patients — risks that marketing language routinely obscures. A 2025 peer-reviewed analysis found that DTC ketamine telehealth creates a “liability gap” in which prescribers operating remotely may lack the clinical infrastructure to manage adverse events, monitor for misuse, or obtain genuinely informed consent, exposing patients to harms that standard in-person psychiatric care would catch earlier, according to this ketamine liability study.

Peptides deepen the problem. Peptides — short amino acid chains marketed for weight loss, muscle repair, sexual function, and longevity — occupy a regulatory gray zone that varies dramatically by state. Researchers examining peptide availability found that state-level regulatory inconsistency, not federal oversight, largely determines whether a patient can obtain these compounds through a telehealth prescription, meaning your zip code shapes your access more than clinical evidence does, per this peptide availability study.

Key patterns consumers should recognize:

Consent theater. Some DTC platforms present digital consent forms as a substitute for genuine informed-consent conversations. The ketamine liability research identifies this as a core ethical failure — a checkbox is not a clinical discussion about dissociation risk, cardiovascular effects, or psychological dependence potential, per this ketamine liability study.
Compounding opacity. Many platforms prescribe compounded versions of peptides or ketamine formulations that are not FDA-approved products. Patients rarely receive clear disclosure that “compounded” means the drug was mixed at a pharmacy, not manufactured under the same quality controls as an approved medication.
Documentation gaps. Telehealth documentation standards remain inconsistent across specialties and platforms. Inadequate records make it harder for patients to dispute a bad outcome or for a subsequent provider to understand what was prescribed and why, a problem flagged in this telemedicine documentation review.
Regulatory arbitrage. Platforms sometimes incorporate in states with looser oversight, then serve patients nationwide. The American College of Physicians has called for consistent telemedicine standards precisely because this arbitrage undermines patient protection, per this ACP position paper.

The liability risk is real. It flows downhill. When a platform’s legal exposure grows, patients face disrupted care, abrupt prescription terminations, and no clear path to follow-up. Before enrolling in any DTC program offering ketamine or peptides, ask the platform directly: who is liable if something goes wrong, and what is the clinical escalation plan?

Documentation Failures: When the Paper Trail Goes Cold

Telehealth documentation failures are not rare edge cases — they are a structural gap that leaves patients without records they may urgently need, and that lets low-quality providers escape accountability. The problem runs from missing visit notes to absent informed-consent logs, and it cuts across specialties.

A global scoping review on telemedicine documentation found that documentation standards in telehealth encounters vary dramatically across settings, with no consistent framework governing what providers must record or retain. That inconsistency matters to patients because your visit note is your evidence — for insurance appeals, for continuity of care, for disputing a charge.

Here is what the documentation gaps look like in practice:

Informed consent records. Providers prescribing off-label treatments through telehealth platforms carry a specific obligation to document that patients understood the risks. Research on off-label ketamine via direct-to-consumer telehealth identifies the absence of documented informed consent as a primary liability and ethical failure — meaning the platform may have no record that you were ever told what you were agreeing to.
Clinical reasoning trails. When a telehealth provider prescribes a controlled substance or a compounded peptide, regulators and payers expect to see documented clinical justification. A study on state-level peptide availability found that prescribing practices in this space outpace the documentation infrastructure meant to support them.
Continuity handoffs. The American College of Physicians position paper on telemedicine explicitly calls for telehealth encounters to generate records transferable to a patient’s primary care provider. Many platforms do not do this. Your telehealth visit exists in a silo.
Medication records for high-stakes treatments. For patients receiving buprenorphine through telehealth, retrospective cohort data show that health services usage patterns are trackable — but only when documentation exists to track them. Gaps in records translate directly into gaps in care coordination.

Regulatory frameworks compound the problem. Research on telepharmacy in Indonesia found that pharmacists operating without regulatory support defaulted to informal, unverifiable documentation practices — a dynamic that mirrors what happens in any telehealth market where oversight lags behind adoption.

Before your visit ends, ask your telehealth provider: Where is my visit note? How do I access it? Will it reach my primary care doctor? If the answer is vague, that vagueness is itself a data point.

This section presents general health system information for consumer awareness purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.

Opioid Treatment and PrEP: Equity Gaps Hidden Inside Oversight Gaps

Telehealth’s oversight gaps fall hardest on two patient populations who need consistent, stigma-free access the most: people seeking medications for opioid use disorder (MOUD) and people seeking PrEP for HIV prevention. Both groups face a system where regulatory inconsistency doesn’t distribute risk evenly — it concentrates harm among patients who already face structural barriers.

The opioid treatment gap is measurable and documented.

A global MOUD telehealth study tracking telehealth programs identifies a consistent cluster of barriers that telehealth was supposed to dissolve: provider reluctance, inconsistent prescribing rules across jurisdictions, and stigma inside clinical workflows all persist inside telehealth platforms, not just in-person settings. The platform changes the delivery channel. It does not automatically change the clinical culture.

Patients using buprenorphine — the most evidence-supported MOUD medication — show measurable differences in health services use depending on whether providers document it for opioid use disorder versus chronic pain, a distinction that shapes how they monitor and continue care, according to buprenorphine cohort research. That documentation asymmetry matters enormously in telehealth, where the clinical record is the encounter.

PrEP access through telehealth carries its own equity fault lines.

Surveillance data on PrEP uptake shows persistent gaps by race, geography, and insurance status — gaps that telehealth expansion has not closed. The PREMISE system protocol was designed specifically because existing data systems couldn’t track whether PrEP programs were actually reaching underserved populations.
Telehealth platforms marketing PrEP as “easy” and “discreet” are selling a real benefit. They are not selling equity. Rural patients, uninsured patients, and patients without reliable broadband remain outside the reach of even the most consumer-friendly platforms.

The oversight gap amplifies both problems.

The American College of Physicians position paper calls explicitly for telehealth policy that addresses health equity — naming it as a core standard, not an aspirational add-on. When state-level rules vary on what telehealth providers must document, follow up on, or report, the patients most likely to fall through are the ones with the fewest alternatives.

Inconsistent documentation standards don’t just create liability exposure for providers, as telemedicine documentation research makes clear. They create care gaps for patients. In MOUD and PrEP, those gaps carry life-or-death stakes.

This section presents general information for educational purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider for guidance specific to your situation.

Global Warning Signs: What Unregulated Telepharmacy Looks Like in Practice

Unregulated telepharmacy produces concrete, documented harms: pharmacists operating without legal frameworks dispense medications without adequate patient verification, skip mandatory counseling steps, and face zero accountability when things go wrong. Researchers examining telepharmacy practice on the ground found exactly this pattern.

A study of Indonesian community pharmacists operating without regulatory support documented pharmacists dispensing prescription medications through messaging apps and phone calls with no standardized verification process, no formal documentation requirements, and no clear liability structure if a patient was harmed. The researchers identified this regulatory vacuum as the direct cause—not a side effect—of unsafe practice.

Watch for these specific warning signs when evaluating a telepharmacy or telehealth-pharmacy hybrid:

No documented prescriber-patient relationship. Legitimate dispensing requires a valid prescription from a provider who has actually evaluated you. Research on off-label ketamine telehealth found that some direct-to-consumer platforms prescribe controlled substances after minimal asynchronous intake forms, with no synchronous clinical encounter—a practice that creates serious liability gaps and patient safety risks.
State licensing opacity. A pharmacy operating across state lines must hold licensure in each state where it ships medications. The American College of Physicians position paper on telemedicine explicitly identifies cross-jurisdictional licensing as a core patient-protection requirement that many platforms quietly sidestep.
Peptide and compounded drug availability with no regulatory disclosure. Research on state-level peptide availability found that access to compounded peptide therapies varies dramatically by state—and that some platforms advertise these substances without disclosing their unapproved status or the compounding pharmacy’s regulatory standing.
Missing counseling documentation. The Indonesian telepharmacy study found that pharmacist counseling—a legal requirement in most jurisdictions—was routinely skipped in unregulated telepharmacy encounters because no system existed to record or enforce it.
Vague or absent medication-for-opioid-use-disorder (MOUD) protocols. Global research on telemedicine-enabled MOUD identified regulatory inconsistency as a primary barrier to safe buprenorphine dispensing via telehealth—meaning patients in some regions receive this high-stakes medication with no standardized follow-up structure.

The pattern across these findings is consistent. Regulatory absence does not simply create inconvenience. It removes the mechanisms that catch errors, flag dangerous interactions, and hold providers accountable. Short of verified state licensure, documented clinical encounters, and transparent compounding disclosures, a telepharmacy platform is asking you to trust marketing copy instead of enforceable standards.

What Watchdogs and Policymakers Should Do Next

Regulators and consumer watchdogs must act on three fronts simultaneously: standardize telehealth documentation requirements, close the state-level regulatory gaps that allow unvetted compounds to reach patients, and build surveillance infrastructure capable of tracking whether telehealth programs actually deliver the outcomes they promise.

Strengthen Documentation Standards Across All Specialties

The American College of Physicians has called explicitly for telehealth documentation standards that match the rigor applied to in-person care. Policymakers should treat that position paper as a floor, not a ceiling. A global scoping review of telemedicine documentation found wide inconsistency in how telehealth encounters are recorded — inconsistency that makes auditing provider legitimacy nearly impossible. Regulators should require:

Structured visit notes with timestamps and provider credentials visible to patients on request
Mandatory disclosure of prescribing rationale for any off-label treatment
Retention of records in formats accessible to state medical boards during investigations

Close State-Level Compound Loopholes

State law, not federal oversight, largely determines which peptides and compounded drugs telehealth platforms can prescribe and ship. Research on state-level peptide availability shows that regulatory patchwork — not clinical evidence — drives what patients can access. State attorneys general should audit telehealth platforms operating across state lines and require that any compound prescribed via telehealth carry documented FDA status and a clear informed-consent disclosure.

Off-label ketamine prescribing through direct-to-consumer telehealth illustrates the stakes. A peer-reviewed analysis of liability risks in DTC ketamine telehealth identifies specific ethical gaps — inadequate screening, minimal follow-up, diffuse accountability — that existing state frameworks have not resolved. Watchdogs should publish platform-by-platform scorecards rating compliance with informed-consent and follow-up standards.

Build Surveillance Systems That Track Real Outcomes

Telehealth marketing offers mostly promises. The PREMISE protocol for tracking PrEP uptake and program impact demonstrates that rigorous, population-level surveillance of telehealth-delivered care is methodologically achievable. Policymakers should fund analogous systems for high-volume telehealth categories — weight loss, mental health, addiction treatment — so that outcome data, not marketing copy, drives consumer choice.

Research on telemedicine-enabled opioid use disorder treatment identifies surveillance gaps as a core barrier to evaluating program quality globally. The U.S. has the infrastructure to lead here. It has not. Congress should tie telehealth platform licensure to mandatory outcome reporting.

This section presents general informational findings and policy analysis. It is not medical advice. Consult a qualified healthcare professional for guidance specific to your situation.

FAQ

What is regulatory arbitrage in telehealth prescribing?

Regulatory arbitrage occurs when telehealth platforms or prescribers deliberately operate from states with looser rules to serve patients in states with stricter ones, effectively bypassing tighter oversight. Research published in Sexual Medicine found this dynamic at work in the availability of peptide therapies across state lines.

Why is off-label ketamine prescribing via telehealth a concern?

A Psychiatric Services study found that direct-to-consumer telehealth platforms offering off-label ketamine face significant liability exposure and ethical questions because existing federal and state frameworks were not designed for this prescribing model. The concern centers on inadequate patient screening, follow-up, and accountability when care is delivered remotely at scale.

What documentation problems exist in telemedicine?

A global scoping review in Neurological Sciences found that telemedicine documentation practices vary widely across health systems and countries, with many encounters lacking the standardized records needed to ensure continuity of care, support liability review, or enable regulatory audits.

How does telehealth oversight affect access to opioid use disorder treatment?

Research in the Journal of Telemedicine and Telecare found that inconsistent regulations, stigma, and prescribing barriers limit who can access telemedicine-based medications for opioid use disorder globally. A separate retrospective cohort study in JMIR Formative Research examined health services usage among buprenorphine patients, highlighting how policy shapes real-world treatment patterns.

What does the American College of Physicians say about telemedicine policy?

A position paper from the American College of Physicians published in Annals of Internal Medicine calls for coherent, evidence-based telemedicine policy that addresses licensure, reimbursement, and quality standards—signaling that major medical bodies view the current regulatory environment as insufficient.

Is this article medical advice?

No. This report is general health information for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional for guidance specific to your situation.

This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.